Devic’s Disease (NMOSD): The Optic Nerve and Spinal Cord Attack Often Confused With MS

Devic’s Disease, now called Neuromyelitis Optica Spectrum Disorder, or NMOSD, is a rare autoimmune neurological condition characterized by inflammation of the optic nerves and spinal cord. The condition was first described by French physician Eugène Devic in 1894 and was called Devic’s Disease for many years. However, modern understanding has revealed that Devic’s original description was part of a broader spectrum of disease, now called Neuromyelitis Optica Spectrum Disorder. NMOSD affects approximately one to five people per million worldwide, making it a rare disorder. The condition causes sudden attacks of optic neuritis, inflammation of the optic nerves, causing temporary or permanent vision loss. It also causes myelitis, inflammation of the spinal cord, causing paralysis and loss of sensation. NMOSD is fundamentally different from Multiple Sclerosis, though the two conditions are often confused because both cause demyelination, damage to the protective coating around nerve fibers. However, NMOSD is a distinct disease with different pathophysiology, different antibodies, different treatment approaches, and different prognosis than MS. Understanding the differences between NMOSD and MS is crucial because treatment approaches differ significantly. What works for MS may not work for NMOSD and may even worsen NMOSD in some cases. Most cases of NMOSD are associated with antibodies against aquaporin-4, a protein found in the central nervous system. These AQP4 antibodies attack cells containing aquaporin-4, causing inflammation and demyelination. Some cases of NMOSD are associated with antibodies against myelin oligodendrocyte glycoprotein, or MOG. These MOG-associated cases may have different features and prognosis. A small percentage of NMOSD cases are seronegative, meaning no antibodies are detected despite typical clinical presentation. NMOSD is a serious condition that can cause permanent disability if not properly treated. However, with appropriate immunosuppressive therapy, disease attacks can be prevented or reduced in frequency and severity. Early diagnosis and appropriate treatment are crucial for achieving the best outcomes. Understanding NMOSD helps distinguish it from MS and ensures appropriate treatment decisions.

How Does Aquaporin-4 Antibodies Cause NMOSD?

To understand NMOSD, we need to learn about aquaporin-4 and how antibodies against it cause disease. Aquaporin-4 is a water channel protein found in cells called astrocytes in the central nervous system. Astrocytes are star-shaped cells that support neurons and maintain the environment around nerve cells. Aquaporin-4 regulates water movement across cell membranes. This water channel is important for maintaining proper fluid balance in the brain and spinal cord. In NMOSD, the immune system produces antibodies against aquaporin-4. These AQP4 antibodies circulate in the blood and cross into the central nervous system. When AQP4 antibodies encounter astrocytes containing aquaporin-4, the antibodies bind to the aquaporin-4 protein. Binding of antibodies activates the complement system, which is part of the immune system. Complement activation causes inflammation and destruction of the astrocytes. Astrocytes are killed by the antibody and complement attack. As astrocytes are destroyed, the supporting functions they provide to neurons are lost. Oligodendrocytes, the cells that produce myelin, are also damaged. Myelin is stripped away from nerve fibers, a process called demyelination. Oligodendrocytes are also killed, preventing remyelination and recovery of nerve function. The inflammation is severe and causes extensive damage to nervous tissue. Unlike MS where inflammation is typically less severe, NMOSD inflammation can be devastating. In the optic nerves, the inflammation causes optic neuritis with loss of vision. In the spinal cord, the inflammation causes myelitis with paralysis and loss of sensation. The inflammation in NMOSD typically affects the optic nerves and spinal cord preferentially. However, inflammation can also affect the brain. Brain involvement in NMOSD is increasingly recognized and includes areas surrounding the ventricles called periventricular regions, areas deep in the brain, and the brain stem. Some people with NMOSD develop brainstem syndrome causing hiccups, nausea, and vomiting as distinctive features. The reason why AQP4 antibodies cause inflammation preferentially in optic nerves and spinal cord is not completely understood. These areas may have higher aquaporin-4 expression. The blood-brain barrier may be more permeable in these regions. Whatever the mechanism, the preferential targeting of optic nerves and spinal cord is a distinguishing feature of NMOSD. Unlike MS where brain lesions are very common, NMOSD typically does not affect the brain extensively, though brain involvement is increasingly recognized. This pattern of involvement helps distinguish NMOSD from MS. Understanding the antibody-mediated mechanism of NMOSD has important implications for treatment. Therapies that reduce antibody production or remove antibodies from circulation are particularly effective. This is why plasma exchange, which removes antibodies from blood, is effective in NMOSD attacks.

What Are the Differences Between NMOSD and Multiple Sclerosis?

NMOSD and Multiple Sclerosis are often confused because both are demyelinating diseases of the central nervous system. However, they are fundamentally different diseases with different causes, different patterns of involvement, different antibodies, and different treatments. Understanding the differences is crucial because treatment appropriate for MS may worsen NMOSD. Multiple Sclerosis is an autoimmune disease where the immune system attacks myelin and oligodendrocytes. MS causes demyelinating lesions scattered throughout the brain and spinal cord. MS typically causes multiple brain lesions. MS shows a characteristic MRI pattern with lesions in characteristic locations including periventricular white matter, infratentorial regions, and cortical regions. MS relapses are typically followed by remission with some recovery of function. MS progresses over years with gradual accumulation of disability. MS is much more common than NMOSD. NMOSD is caused by antibodies against aquaporin-4 or MOG. NMOSD preferentially affects optic nerves and spinal cord. Brain involvement in NMOSD is less common than in MS, though increasingly recognized. Brain lesions in NMOSD, when present, are in different locations than typical MS lesions. NMOSD relapses are typically more severe than MS relapses. Recovery from NMOSD attacks is often incomplete, leaving permanent deficits. NMOSD is a more aggressive disease with more severe attacks than MS. The specific antibodies differ. MS is not typically associated with aquaporin-4 or MOG antibodies. NMOSD is usually AQP4 antibody positive or sometimes MOG antibody positive. Serology helps distinguish the two diseases. The MRI pattern differs. MS shows multiple brain lesions in characteristic locations. NMOSD shows preferential spinal cord and optic nerve involvement with less brain involvement. Spinal cord lesions in NMOSD are often longitudinally extensive, extending over multiple spinal cord segments. Optic nerve involvement differs. In MS, optic neuritis occurs but is typically less severe than in NMOSD. In NMOSD, optic neuritis is often severe and bilateral. Treatment approaches differ significantly. MS is treated with disease-modifying therapies including interferons, glatiramer acetate, monoclonal antibodies, and other agents. Many of these therapies are not effective for NMOSD and some may worsen NMOSD. NMOSD is treated with immunosuppressive therapy focused on preventing attacks. Plasma exchange is effective in NMOSD attacks. Rituximab targeting B cells is effective in NMOSD. Prognosis differs. MS has variable prognosis but many people have relatively stable disease or slow progression. NMOSD without treatment has poor prognosis with frequent severe attacks leading to permanent disability. However, with appropriate preventive immunosuppressive therapy, NMOSD can be controlled. Early diagnosis and appropriate treatment are crucial because misdiagnosis as MS and treatment with MS therapies can worsen outcomes in NMOSD.

What Are the Main Symptoms and Signs of NMOSD?

NMOSD causes acute attacks of neurological symptoms due to inflammation of optic nerves and spinal cord. Optic neuritis causes sudden vision loss. Vision loss typically affects one eye initially, though both eyes may be affected. Vision loss may be complete or partial. Patients describe darkness or dimming of vision. Pain with eye movement is characteristic of optic neuritis. Loss of color vision is common. Visual field defects may occur. Vision loss typically develops over hours to days. Vision loss may improve with treatment but permanent vision loss is common. Recurrent episodes of optic neuritis can lead to blindness. Myelitis causes spinal cord inflammation with sudden neurological deficits. Weakness or paralysis develops suddenly, often over hours to days. Paraplegia, or paralysis of both legs, is common. Tetraplegia, or paralysis of all four limbs, occurs if cervical spinal cord is affected. Mild weakness or severe complete paralysis can occur. Sensory loss accompanies weakness. Loss of sensation develops in legs or trunk depending on spinal cord level affected. A sensory level indicating the spinal cord level of involvement may be present. Back pain at the level of spinal cord inflammation is common. Bowel and bladder dysfunction develops. Urinary retention or incontinence occurs. Constipation or fecal incontinence develops. These can be severely disabling. Lhermitte’s sign, a tingling sensation down the spine with neck bending, is common. Spasticity develops as inflammation resolves. Brainstem involvement causes distinctive symptoms. Intractable hiccups, a very characteristic symptom of NMOSD brainstem involvement, may occur. Nausea and vomiting are common. These symptoms can be severe and difficult to treat. Loss of consciousness, respiratory failure, and other severe symptoms can occur with brainstem involvement. Pain is very common in NMOSD attacks. The pain can be severe and difficult to control. Central pain syndrome, where abnormal pain signals develop from damaged spinal cord, can be chronic and debilitating. Fatigue is profound and common. The fatigue appears neurological and is often out of proportion to other symptoms. Fatigue severely limits activity and function. Temperature sensation changes occur. Some patients describe temperature sensation loss or distortion. Cognitive symptoms may develop if brain is involved. Memory problems and other cognitive changes occur. Depression and mood changes result from disease burden and neurological involvement. Sexual dysfunction occurs from spinal cord and autonomic involvement. The attacks in NMOSD are typically more severe and cause more permanent disability than MS attacks. Recovery from attacks is often incomplete. Permanent vision loss and permanent paralysis are common after NMOSD attacks. This aggressive nature of NMOSD distinguishes it from MS where recovery is usually more complete. Multiple attacks lead to accumulating disability.

How is NMOSD Detected and Diagnosed?

NMOSD is often misdiagnosed as MS because the two conditions present similarly. Proper diagnosis requires recognition of the pattern of involvement and specific antibody and imaging findings. Clinical history of optic neuritis followed by myelitis is highly suggestive of NMOSD. The temporal association of optic neuritis and myelitis, even if separated by months or years, helps suggest NMOSD. Severe vision loss in optic neuritis. Severe paraplegia or tetraplegia in myelitis. Long duration of symptoms are concerning for NMOSD. Physical examination reveals neurological deficits. Vision testing shows vision loss or visual field defects from optic neuritis. Examination of pupils may show afferent pupillary defect from optic nerve damage. Neurological examination shows weakness or paralysis and sensory loss from myelitis. Spinal cord level may be determined. MRI of the brain, orbits, and spinal cord is done. Optic nerve MRI shows inflamed optic nerves in optic neuritis. Spinal cord MRI shows inflamed spinal cord in myelitis. In NMOSD, spinal cord lesions often extend longitudinally over three or more spinal cord segments, called longitudinally extensive transverse myelitis or LETM. This long longitudinal extent is more characteristic of NMOSD than MS. Brain MRI in NMOSD may show no lesions or may show lesions in different patterns than MS. Brain lesions in NMOSD often involve areas around the ventricles or brainstem. The brain lesion pattern differs from typical MS. Aquaporin-4 antibody testing is crucial for diagnosis. AQP4 antibody seropositivity strongly supports NMOSD diagnosis. About seventy percent of NMOSD patients are AQP4 seropositive. MOG antibody testing identifies MOG-associated NMOSD. Some seronegative patients have MOG antibodies. About ten percent are MOG positive. MOG-associated NMOSD may have somewhat different features and prognosis than AQP4-associated disease. Lumbar puncture with cerebrospinal fluid analysis is often done. CSF may show pleocytosis, elevated protein, and oligoclonal bands. CSF findings help confirm inflammation. Evoked potentials measuring electrical activity in visual and spinal pathways may be done. Visual evoked potentials are prolonged or absent in optic neuritis. Somatosensory evoked potentials are abnormal in myelitis. These objectively demonstrate nerve involvement. Optical coherence tomography, or OCT, measures optic nerve thickness. OCT shows thinning of the optic nerve from prior optic neuritis, even after vision recovers. OCT can help identify prior attacks and predict recurrence risk. Testing for other autoimmune diseases and infections is done. Systemic autoimmune diseases like lupus can be associated with NMOSD-like disease. Infectious causes of myelitis must be ruled out. Misdiagnosis as MS is common. Many people with NMOSD are initially diagnosed with MS and treated with MS therapies that are ineffective and sometimes harmful. Early correct diagnosis allows appropriate treatment.

What Health Complications Do People with NMOSD Face?

People with NMOSD face serious neurological complications from the severe attacks of inflammation. Without appropriate preventive treatment, NMOSD is a severe and disabling disease. Permanent vision loss is a major complication. Recurrent optic neuritis attacks lead to progressive vision loss. Many people develop blindness or severe visual impairment from multiple attacks. Vision loss is permanent and cannot be reversed. Blindness severely affects independence and quality of life. Permanent paralysis results from severe spinal cord attacks. Paraplegia confines people to wheelchairs. Tetraplegia with arm paralysis severely limits function. Permanent paralysis from NMOSD attacks is common. Many people have incomplete recovery after attacks leaving residual deficits. Repeated attacks cause accumulating paralysis and disability. Spasticity develops from spinal cord damage. Muscle spasticity can be severe and disabling. Spasticity limits function and causes pain. Bowel and bladder dysfunction is severely disabling. Permanent catheter dependence is common. Bowel management requires intensive daily routines. Incontinence affects quality of life and social function. Chronic pain develops from spinal cord damage. Central pain syndrome causes severe pain that is difficult to treat. Pain interferes with sleep, function, and emotional wellbeing. Pain may become the most limiting symptom. Respiratory compromise occurs with cervical myelitis. Diaphragm weakness impairs breathing. Ventilator dependence may become necessary. Respiratory failure from NMOSD is life-threatening. Brainstem attacks causing hiccups and nausea can be severely debilitating and difficult to treat. Intractable hiccups can persist for weeks. Severe nausea and vomiting cause weight loss. Some patients require feeding tubes. Cognitive changes and memory problems result from brain involvement. Dementia-like decline can occur. Psychiatric symptoms including depression and psychosis may develop. Sexual dysfunction results from spinal cord and autonomic damage. Erectile dysfunction and loss of sensation affect sexual function. Relationships are strained by sexual dysfunction. Infections become more common from bladder catheterization and other complications. Recurrent urinary tract infections are common. Skin infections from immobility develop. Infection can progress to sepsis. Life expectancy may be shortened. Complications including respiratory failure, severe infections, and autonomic dysfunction can be life-threatening. NMOSD-related mortality exists but is reduced with appropriate treatment. Depression and suicide risk increase with the severe disability and permanent vision loss and paralysis. Mental health support is essential. Without appropriate preventive immunosuppressive therapy, NMOSD is severely disabling. With appropriate therapy preventing attacks, complications can be substantially prevented.

What Treatments Help People with NMOSD?

Treatment for NMOSD focuses on reducing inflammation during acute attacks and preventing future attacks through long-term immunosuppression. Unlike MS, where disease-modifying therapies may worsen NMOSD, NMOSD treatment focuses on preventing antibody-mediated attacks. Acute attack treatment aims to rapidly reduce inflammation. High-dose intravenous methylprednisolone one gram daily for three to five days is given. IV corticosteroids rapidly reduce inflammation. Within days to weeks, inflammation begins to resolve. Early corticosteroid treatment limits permanent nerve damage. Plasma exchange is highly effective in NMOSD attacks. Plasma exchange removes antibodies from blood. Five to seven exchanges over one to two weeks are typically done. Plasma exchange can dramatically improve outcomes in severe attacks. Plasma exchange is particularly effective in NMOSD because the disease is antibody-mediated. Unlike MS where plasma exchange is less effective, plasma exchange is often highly effective in NMOSD. Intravenous immunoglobulin, or IVIG, may be used as alternative immune modulation. IVIG may be used if plasma exchange is not available. IVIG has immunomodulatory effects. Long-term preventive immunosuppressive therapy prevents attacks. The goal is to prevent future attacks and preserve vision and function. Rituximab is a monoclonal antibody targeting B cells. Rituximab depletes B cells that produce AQP4 antibodies. Rituximab is highly effective for preventing NMOSD attacks. Rituximab can induce remission with attacks becoming rare or absent. Rituximab has become a first-line preventive therapy for NMOSD. Azathioprine suppresses immune function. Long-term azathioprine may prevent attacks. Azathioprine combined with corticosteroids can be effective. However, rituximab is often preferred. Mycophenolate mofetil suppresses immune function. Long-term MMF can prevent attacks. MMF is an alternative to azathioprine. Eculizumab is a complement inhibitor that blocks complement activation. Complement activation is central to NMOSD pathophysiology. Eculizumab blocks complement C5, preventing complement activation. Eculizumab has been highly effective in clinical trials for NMOSD prevention. Eculizumab is being used for NMOSD treatment. Tocilizumab is an IL-6 receptor inhibitor. IL-6 is important in NMOSD inflammation. Tocilizumab may help prevent attacks in some cases. Inebilizumab targets B cells more specifically than rituximab. Inebilizumab shows promise in NMOSD treatment. Multiple new therapies are emerging. Long-term corticosteroids are used as adjunctive therapy but carry risks with prolonged use. Lowest effective dose is used. Immunosuppression typically requires lifelong therapy. Attacks recur if preventive therapy is stopped. Symptomatic treatment addresses specific complications. Pain management. Spasticity management with medications and physical therapy. Bowel and bladder management. Psychiatric support for depression and anxiety. Vision rehabilitation for those with vision loss. Spinal cord rehabilitation for those with paralysis. Regular monitoring is important. Periodic antibody testing assesses AQP4 antibody levels. Some evidence suggests higher antibody levels predict higher attack risk. Imaging periodically assesses for new lesions. Clinical assessment monitors for new symptoms. Early detection of new attacks allows prompt treatment.

Living with NMOSD

Living with NMOSD is profoundly challenging due to the unpredictability of attacks, the severity of deficits from attacks, and the permanent disability that often results. For people newly diagnosed with NMOSD, particularly after misdiagnosis as MS, the diagnosis is devastating. Learning that they have a rare, aggressive neurological disease is overwhelming. However, understanding that with appropriate preventive therapy attacks can be largely prevented offers hope. Patient education about NMOSD, distinguishing it from MS, and emphasizing the importance of appropriate treatment is crucial. Patients previously misdiagnosed with MS need to understand the difference and why their treatment must change. Attack prevention through immunosuppressive therapy becomes the primary focus. Taking immunosuppressive medications consistently is essential. Missing doses risks attacks. Medication side effects require management. Regular monitoring for medication toxicity is necessary. Awareness of potential attack symptoms helps prompt recognition. Visual symptoms including sudden vision changes should prompt immediate attention. Neurological symptoms including weakness or paralysis should prompt immediate evaluation. Early recognition and treatment of attacks minimizes permanent damage. Uncertainty about when the next attack might occur causes anxiety. Unpredictability of disease activity affects life planning. Work, school, and social engagement are affected by concern about attacks. Some people restrict activity to minimize potential triggers. Stress management becomes important. Physical stress like infection or overexertion may trigger attacks. Emotional stress may trigger attacks. Stress management techniques and lifestyle modifications help prevent triggers. Vision loss affects independence. Those with significant vision loss require adaptations. Orientation and mobility training helps navigate without sight. Assistive technology helps with reading and daily tasks. Vision loss affects employment and limits many activities. Blindness from repeated attacks requires major life adaptations. Paralysis affects mobility and independence. Those with paraplegia or tetraplegia depend on wheelchairs. Architectural accessibility becomes crucial. Vehicle modifications enable driving for those with sufficient upper extremity function. Assistance with self-care may be necessary. Bowel and bladder management dominates daily life. Catheterization routine becomes daily necessity. Bowel programs require time and planning. These essential medical needs are private concerns that become necessary daily management. Sexual dysfunction affects relationships. Erectile dysfunction in men. Sensory loss and physical limitations in both sexes. Communication with partners about adaptations helps maintain relationships. Chronic pain from spinal cord damage severely impacts quality of life. Pain management is complex. Multiple medications with variable effectiveness are tried. Pain interferes with sleep, work, and leisure. Pain management strategies are crucial. Fatigue is profound and often underestimated. Neurological fatigue differs from normal tiredness. Activity limitation because of fatigue. Energy management and pacing help function despite fatigue. Work and career implications are significant. Many cannot continue previous work due to disability. Retraining for different work may be possible. Disability benefits may be necessary. Financial stress from medical costs and lost income. Mental health challenges are common. Depression from chronic disease and permanent disability. Anxiety about future attacks. Post-traumatic stress from sudden onset of severe disease. Counseling and support groups help. Medication for depression and anxiety often needed. Maintaining relationships within limitations is important. Family strain from disease burden. Caregiver burden affects family members. Family counseling helps families adjust. Social connection prevents isolation. Support groups for people with NMOSD provide community. Online communities connect people. Maintaining meaningful activities and relationships within limitations. With appropriate preventive immunosuppressive therapy preventing attacks, appropriate management of existing deficits, pain management, mental health support, rehabilitation services, family support, and lifestyle adaptations within limitations, many people with NMOSD can achieve stability and maintain meaningful quality of life despite the serious challenges of this rare disease.

Frequently Asked Questions About NMOSD

FAQ 1: Is NMOSD the same as Multiple Sclerosis? NMOSD and MS are different diseases. Both cause demyelination and can present similarly, which is why they are often confused. However, they are fundamentally different. NMOSD is caused by antibodies against aquaporin-4 or MOG. MS is not typically associated with these antibodies. NMOSD preferentially affects optic nerves and spinal cord. MS causes widespread brain and spinal cord lesions. The MRI patterns are different. Treatment differs significantly. MS therapies like interferon and glatiramer acetate are not effective for NMOSD and may worsen NMOSD. NMOSD requires different treatment. Proper diagnosis is crucial because misdiagnosis as MS and treatment with MS therapies can worsen outcomes. Antibody testing and MRI patterns help distinguish the two diseases.

FAQ 2: What is the difference between NMOSD and Devic’s Disease? Devic’s Disease is the older name for what is now called Neuromyelitis Optica Spectrum Disorder or NMOSD. Devic’s Disease originally referred specifically to the combination of optic neuritis and myelitis in the same patient. Modern understanding has expanded this to include the broader spectrum of disease with various antibody associations and brain involvement. NMOSD is the current comprehensive term. Devic’s Disease is an older term still sometimes used but NMOSD is the modern terminology. The terms refer to essentially the same disease concept.

FAQ 3: Can NMOSD cause permanent blindness? Yes, NMOSD can cause permanent blindness. Optic neuritis in NMOSD is often severe. Recurrent attacks of optic neuritis lead to progressive vision loss. Vision loss from each attack often does not completely recover. Repeated attacks compound vision loss. Many people with NMOSD develop severe visual impairment or blindness from multiple attacks. Preventive therapy that prevents attacks is crucial for preserving vision. Early recognition and treatment of attacks minimizes vision loss. Vision lost from spinal cord inflammation cannot be recovered. Preventing future attacks through appropriate therapy is essential for protecting remaining vision.

FAQ 4: Is NMOSD hereditary? NMOSD is not hereditary. It is not passed down through families. NMOSD develops due to autoimmune antibodies against aquaporin-4 or MOG that develop during a person’s lifetime. However, genetic predisposition to autoimmune disease runs in families. People with family history of autoimmune diseases have higher risk of autoimmune disease development. Specific genetic profiles increase autoimmune disease risk. Environmental triggers in genetically susceptible people lead to disease development. Family members do not inherit NMOSD itself. Family members should be aware of autoimmune disease risk but do not need routine screening for NMOSD.

FAQ 5: What is the prognosis for NMOSD? Without treatment, NMOSD has a poor prognosis. Frequent severe attacks lead to permanent vision loss and paralysis. Many people without treatment become blind and paralyzed. With appropriate preventive immunosuppressive therapy, prognosis improves substantially. Rituximab and other preventive therapies can reduce attack frequency dramatically. Many people on preventive therapy have few or no attacks. Vision and function can be preserved with appropriate therapy. Early diagnosis and appropriate treatment improve prognosis significantly. Factors influencing prognosis include disease severity, antibody type, and response to therapy.

References and Further Reading

For more information about NMOSD and Devic’s Disease, you can visit several trusted and authoritative sources that provide detailed information for patients and families dealing with this rare demyelinating disorder. The World Health Organization at WHO.int provides comprehensive information about demyelinating diseases including NMOSD and how it differs from MS. The Guthy Jackson Charitable Foundation at GuchyJackson.org offers excellent patient education, family resources, support communities, information about NMOSD treatments, and updates about research developments in NMOSD care and understanding. The Transverse Myelitis Association at Myelitis.org provides resources for spinal cord inflammatory diseases including NMOSD and myelitis. MedlinePlus, a service of the National Library of Medicine at MedlinePlus.gov, has detailed medical information about NMOSD written in language that patients and families can easily understand without specialized medical knowledge. The National Institutes of Health at NIH.gov provides scientific information about NMOSD research, ongoing clinical trials, and the latest discoveries about aquaporin-4 antibodies and NMOSD pathophysiology. The five main reference links are: 1) WHO.int – Demyelinating Diseases, 2) Guthy Jackson Charitable Foundation, 3) Transverse Myelitis Association, 4) MedlinePlus – NMOSD, and 5) National Institutes of Health.

Disclaimer

This article adapts publicly available information from WHO’s NMOSD and demyelinating disease information pages. This content is for informational and educational purposes only and does not constitute medical advice. ObserverVoice.com is a news and information platform — not a healthcare provider. If you or someone you know has been diagnosed with NMOSD or shows signs of this condition including acute vision loss, optic neuritis, acute spinal cord inflammation with weakness or paralysis, sensory loss, bowel or bladder dysfunction, or other neurological symptoms, please consult immediately with qualified healthcare professionals, neurologists, neuroimmunologists, and NMOSD specialists for proper emergency diagnostic evaluation with MRI of brain and spine, aquaporin-4 and MOG antibody testing, lumbar puncture, and appropriate treatment with corticosteroids, plasma exchange, and long-term preventive immunosuppression. Early accurate diagnosis distinguishing NMOSD from MS is crucial for appropriate treatment. For more information, visit WHO.int and ObserverVoice.com.